Michael J. Morris
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Radiology, Nuclear Medicine and Imaging top 0.05%
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
Papers in
-
- Prostate Cancer Treatment and Research 287
- Prostate Cancer Diagnosis and Treatment 34
- Renal cell carcinoma treatment 24
-
- Radiopharmaceutical Chemistry and Applications 163
- Medical Imaging Techniques and Applications 34
- Co-authors
- Howard I. Scher (149 shared papers)Steven M. Larson (67 shared papers)Eric J. Small (40 shared papers)Susan Halabi (48 shared papers)Tomasz M. Beer (17 shared papers)William Kevin Kelly (32 shared papers)Glenn Heller (42 shared papers)Karim Fizazi (40 shared papers)
- Journals
- Journal of Clinical Oncology (173 papers)Journal of Nuclear Medicine (24 papers)Clinical Cancer Research (21 papers)Annals of Oncology (17 papers)Cancer (16 papers)
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Michael J. Morris
452 papers receiving 18.4k citations
Michael J. Morris's Hit Papers
Peers
Comparison fields: 5 of 174
- Pulmonary and Respiratory Medicine 10.8k
- Radiology, Nuclear Medicine and Imaging 4.8k
- Cancer Research 2.3k
- Oncology 3.9k
- Endocrinology, Diabetes and Metabolism 770
Countries citing papers authored by Michael J. Morris
This map shows the geographic impact of Michael J. Morris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Morris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Morris more than expected).
Fields of papers citing papers by Michael J. Morris
This network shows the impact of papers produced by Michael J. Morris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Morris. The network helps show where Michael J. Morris may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael J. Morris, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 467 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group Hit paper breakdown → | 2008 | 1714 |
| 2 | Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2021 | 1582 |
| 3 | Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study Hit paper breakdown → | 2010 | 811 |
| 4 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 512 |
| 5 | Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401 Hit paper breakdown → | 2012 | 350 |
| 6 | Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2014 | 329 |
| 7 | 2010 | 318 | |
| 8 | 1980 | 316 | |
| 9 | Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2013 | 313 |
| 10 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Hit paper breakdown → | 2018 | 272 |
| 11 | 2003 | 267 | |
| 12 | A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18 F-DCFPyL in Prostate Cancer Patients (OSPREY) Hit paper breakdown → | 2021 | 255 |
| 13 | Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study Hit paper breakdown → | 2021 | 250 |
| 14 | Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. | 2004 | 224 |
| 15 | 2010 | 214 | |
| 16 | 2013 | 205 | |
| 17 | 2018 | 205 | |
| 18 | 2018 | 193 | |
| 19 | 2009 | 178 | |
| 20 | 2007 | 173 |
About Michael J. Morris
Michael J. Morris is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging, Oncology, Cancer Research and Molecular Biology, having authored 467 papers that have together received 18.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (287 papers), Radiopharmaceutical Chemistry and Applications (163 papers), Cancer, Lipids, and Metabolism (35 papers), Medical Imaging Techniques and Applications (34 papers), Prostate Cancer Diagnosis and Treatment (34 papers), Cancer Treatment and Pharmacology (25 papers), Renal cell carcinoma treatment (24 papers) and Bone health and treatments (21 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (10.8k citations), Radiology, Nuclear Medicine and Imaging (4.8k citations), Cancer Research (2.3k citations), Oncology (3.9k citations) and Endocrinology, Diabetes and Metabolism (770 citations). Michael J. Morris has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Howard I. Scher, Steven M. Larson, Eric J. Small, Susan Halabi, Tomasz M. Beer, William Kevin Kelly, Glenn Heller, Karim Fizazi, Susan F. Slovin and Celestia S. Higano. Their work appears in journals such as Journal of Clinical Oncology, Journal of Nuclear Medicine, Clinical Cancer Research, Annals of Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.